Preexisting Poliovirus‐Specific IgA in the Circulation Correlates with Protection against Virus Excretion in the Elderly

Center for Infectious Diseases Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
The Journal of Infectious Diseases (Impact Factor: 6). 04/2008; 197(5):698-706. DOI: 10.1086/527487
Source: PubMed


Epidemiological studies have indicated that at least 10% of the Dutch elderly do not have poliovirus serotype-specific neutralizing antibody titers and might be at risk for poliovirus infection. Previously we established that memory immunity does not protect the elderly against poliovirus replication. In this study, we investigated whether preexisting immunoglobulin (Ig) A protects against poliovirus infection.
Elderly individuals (n = 383), divided into seronegative and seropositive groups, were challenged with monovalent oral poliovirus vaccine (mOPV), either serotype 1 or serotype 3. After challenge, poliovirus serotype-specific circulating and salivary IgA responses were measured by enzyme-linked immunosorbent assays, and poliovirus excretion in stool was measured.
The majority of elderly persons without preexisting IgA excreted poliovirus in the stool. In contrast, most elderly persons seropositive for IgA did not excrete poliovirus. Significant inverse correlations were found between preexisting titers of poliovirus serotype-specific circulating IgA and virus excretion. Challenge with mOPV (re)induced IgA responses; low salivary IgA responses correlated with that in the circulation but not with virus excretion.
These results indicate that preexisting IgA values in the circulation correlate with protection against poliovirus infection in the elderly. This further implies that persons without preexisting IgA might contribute to the circulation of poliovirus and therefore may threaten its eradication.

Download full-text


Available from: Tineke Herremans, Jun 11, 2014
  • Source
    • "Shedding of polio virus is considered the principal marker for protection and studies have implicated intestinal IgA as one of the effector mechanisms to reduce shedding of virus [42]. We therefore examined different vaccine strategies with CAF01 with the aim of generating intestinal IgA. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The development of new low cost inactivated polio virus based vaccines (IPV) is a high priority, and will be required to eradicate polio. In addition, such a vaccine constitutes the only realistic polio vaccine in the post-eradication era. One way to reduce the cost of a vaccine is to increase immunogenicity by use of adjuvants. The CAF01 adjuvant has previously been shown to be a safe and potent adjuvant with several antigens, and here we show that in mice IPV formulated with CAF01 induced increased systemic protective immunity measured by binding and neutralization antibody titers in serum. CAF01 also influenced the kinetics of both the cellular and humoral response against IPV to produce a faster, as well as a stronger, response, dominated by IgG2a, IgG2b, and IgG2c isotypes as well as IPV specific T cells secreting IFN-γ/IL-2. Finally, as intestinal immunity is also a priority of polio vaccines, we present a vaccine strategy based on simultaneous priming at an intradermal and an intramuscular site that generate intestinal immune responses against polio virus. Taken together, the IPV-CAF01 formulation constitutes a new promising vaccine against polio with the ability to generate strong humoral and cellular immunity against the polio virus.
    Full-text · Article · Jun 2014 · PLoS ONE
  • Source
    • "An intestinal IgA response is also induced with the live replicating oral polio vaccine (OPV) and it is surmised that OPV prevents infection through IgA-mediated viral neutralization in the intestine. Live poliovirus vaccine appears to induce long-lived memory immune responses as elderly people who received this vaccine and still had detectable serum and salivary IgA were resistant to reinfection (56). In addition, IPV vaccination of individuals that were 20–44 years of age and had previously been vaccinated with OPV induced IgA+ α4β7+ antibody secreting cell by 7 days post vaccine but not in individuals of similar age previously vaccinated with IPV, which does not induce intestinal IgA responses. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Viral gastroenteritis is one of the leading causes of diseases that kill ~2.2 million people worldwide each year. IgA is one of the major immune effector products present in the gastrointestinal tract yet its importance in protection against gastrointestinal viral infections has been difficult to prove. In part this has been due to a lack of small and large animal models in which pathogenesis of and immunity to gastrointestinal viral infections is similar to that in humans. Much of what we have learned about the role of IgA in the intestinal immune response has been obtained from experimental animal models of rotavirus infection. Rotavirus-specific intestinal IgA appears to be one of the principle effectors of long term protection against rotavirus infection. Thus, there has been a focus on understanding the immunological pathways through which this virus-specific IgA is induced during infection. In addition, the experimental animal models of rotavirus infection provide excellent systems in which new areas of research on viral-specific intestinal IgA including the long term maintenance of viral-specific IgA.
    Full-text · Article · Nov 2013 · Frontiers in Immunology
  • Source
    • "Only one study from 20 years ago showed a correlation for FHA and PT between serum IgA and IgA levels in saliva of pertussis-infected individuals. The diagnostic value of salivary IgA seemed rather weak for pertussis [27], whereas circulating pathogen-specific IgA antibodies might reflect those at the mucosal surfaces as demonstrated for rotavirus and poliovirus [28], [29], [30]. In general, mucosal IgA responses are important in the protection against pathogens as found in newborns and patients with IgA deficiency [31], [32]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Whooping cough is a respiratory disease caused by Bordetella pertussis, which induces mucosal IgA antibodies that appear to be relevant in protection. Serum IgA responses are measured after pertussis infection and might provide an additional role in pertussis diagnostics. However, the possible interfering role for pertussis vaccinations in the induction of serum IgA antibodies is largely unknown. We compared serum IgA responses in healthy vaccinated children between 1 and 10 years of age with those in children who despite vaccinations recently were infected with Bordetella pertussis. All children have been vaccinated at 2, 3, 4 and 11 months of age with either the Dutch whole-cell pertussis (wP) vaccine or an acellular pertussis (aP) vaccine and additionally received an aP booster vaccination at 4 years of age. Serum IgA responses to pertussis toxin (PT), filamentous heamagglutinin (FHA) and pertactin (Prn) were measured with a fluorescent multiplex bead-based immuno-assay. An ELISPOT-assay was used for the detection of IgA-memory B-cells specific to these antigens. Serum IgA levels to all pertussis vaccine antigens were significantly higher in infected children compared with healthy children. High correlations between anti-PT, anti-FHA or anti-Prn IgA and IgG levels were found in infected children and to some degree in wP primed children, but not at all in aP primed children. Highest numbers of IgA-pertussis-specific memory B-cells were observed after infection and generally comparable numbers were found after wP and aP vaccination. This study provides new insight in the diagnostic role for serum IgA responses against PT in vaccinated children. Since aP vaccines induce high serum IgG levels that interfere with pertussis diagnostics, serum IgA-PT levels will provide an additional diagnostic role. High levels of serum IgA for PT proved specific for recent pertussis infection with reasonable sensitivity, whereas the role for IgA levels against FHA and Prn in diagnosing pertussis remains controversial.
    Full-text · Article · Nov 2011 · PLoS ONE
Show more